{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Brooks Laboratories Ltd
Brooks Laboratories Ltd is Rated Sell
Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Brooks Laboratories Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent
At Rs 69.99, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 4.98% on 09 Jun 2026, with buyers queuing and no sellers willing to part with shares.
Brooks Laboratories Ltd Locks at Lower Circuit With 4.99% Loss — Sellers Queue, No Buyers in Sight
At Rs 65.13, sellers were still queuing — but there were no buyers willing to take the other side. Brooks Laboratories Ltd locked at its lower circuit of 4.99% on 2 Jun 2026, with unfilled sell orders and a frozen price, reflecting persistent selling pressure in a micro-cap stock.
Brooks Laboratories Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent
At Rs 68.55, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 4.99% on 1 Jun 2026, with buyers queuing and no sellers willing to part with shares.
Brooks Laboratories Ltd is Rated Sell by MarketsMOJO
Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Feb 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 31 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Brooks Laboratories Q4 FY26: Profit Plunge Raises Questions on Operational Sustainability
Brooks Laboratories Ltd., a contract manufacturing pharmaceutical company, reported consolidated net profit of ₹1.52 crores for Q4 FY26, marking a sharp decline of 72.36% quarter-on-quarter and a troubling 204.11% year-on-year contraction. The Himachal Pradesh-based micro-cap company, with a market capitalisation of ₹194.00 crores, witnessed its stock surge 5.00% to ₹65.75 following the results announcement, though the broader context reveals a company grappling with severe operational headwinds and margin compression.
Brooks Laboratories Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent
At Rs 65.29, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 5% on 29 May 2026, with buyers queuing and no sellers willing to part with shares.
Brooks Laboratories Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent
At Rs 62.19, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 5% on 27 May 2026, with buyers queuing and no sellers willing to part with shares.
Brooks Laboratories Ltd Locks at Upper Circuit With 5.0% Gain — Buyers Queue, Sellers Absent
At Rs 59.23, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 5.0% on 26 May 2026, with buyers queuing and no sellers willing to part with shares.
Brooks Laboratories Ltd Locks at Upper Circuit With 4.99% Gain — Buyers Queue, Sellers Absent
At Rs 56.41, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 4.99% on 25 May 2026, with buyers queuing and no sellers willing to part with shares.
Brooks Laboratories Ltd Locks at Upper Circuit With 4.98% Gain — Buyers Queue, Sellers Absent
At Rs 53.73, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 4.98% on 22 May 2026, with buyers queuing and no sellers willing to part with shares.
Brooks Laboratories Ltd is Rated Sell
Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Brooks Laboratories Ltd Locks at Upper Circuit With 4.53% Gain — Buyers Queue, Sellers Absent
At Rs 48.42, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 4.53% on 19 May 2026, with buyers queuing and no sellers willing to part with shares.
Brooks Laboratories Falls 8.21%: Circuit Hits and Volatility Define the Week
Brooks Laboratories Ltd experienced a turbulent week from 11 to 15 May 2026, closing down 8.21% to Rs.46.72, significantly underperforming the Sensex which declined 2.63% over the same period. The week was marked by extreme volatility, with the stock hitting both its lower and upper circuit limits on consecutive days, reflecting sharp swings in investor sentiment amid heavy selling and buying pressures.
Brooks Laboratories Ltd Locks at Upper Circuit With 3.88% Gain — Buyers Queue, Sellers Absent
At Rs 49.83, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 3.88% on 12 May 2026, with buyers queuing and no sellers willing to part with shares.
Brooks Laboratories Ltd Locks at Lower Circuit With 3.06% Loss — Sellers Queue, No Buyers in Sight
At Rs 48.4, Brooks Laboratories Ltd locked at its lower circuit on 11 May 2026, reflecting a 3.06% decline within a 5% price band. Despite sellers lining up to exit, there were no buyers willing to absorb the supply, resulting in a freeze at the floor price and unfilled sell orders that highlight the stock’s current liquidity challenges.
Brooks Laboratories Ltd Falls 8.44%: 3 Key Events Shaping the Week
Brooks Laboratories Ltd experienced a turbulent week from 4 to 8 May 2026, closing down 8.44% despite intermittent sharp rallies. The stock hit upper circuit limits twice amid strong buying pressure but ultimately succumbed to heavy selling, underperforming the Sensex which gained 1.25% over the same period. This review analyses the key events driving the stock’s volatile performance and the implications for investors.
Brooks Laboratories Ltd is Rated Sell
Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Brooks Laboratories Ltd Locks at Lower Circuit With 4.99% Loss — Sellers Queue, No Buyers in Sight
At Rs 49.93, sellers were still queuing — but there were no buyers willing to take the other side. Brooks Laboratories Ltd locked at its lower circuit of 4.99% on 8 May 2026, with unfilled sell orders and a frozen price that capped losses for the session.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
